ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2296

The Value of Ultrasound to Follow Glandular Disease in Sjogren’s Disease Patients

Katja Perdan Pirkmajer1, Katja Lakota2, Sonja Praprotnik1, Ziga Rotar3 and Alojzija Hocevar4, 1University Medical Centre Ljubljana, Ljubljana, Slovenia, 2UMC Ljubljana, Ljubljana, Slovenia, 3University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 4University Medical Center Ljubljana, LJUBLJANA, Slovenia

Meeting: ACR Convergence 2024

Keywords: Sjögren's syndrome, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Salivary gland (SG) ultrasound (US) helps to diagnose and stratify patients with Sjögren’s disease (SjD). However, US studies evaluating morphological changes over time are scarce. Therefore, we aimed to evaluate the potential progression of US morphological changes of SG in a well-defined SjD cohort.

Methods: One hundred and fifty-one SjD patients diagnosed between January 2016 and December 2018, and fulfilling the ACR/EULAR 2016 classification criteria1 were invited to participate in a follow- up (FU) US study that was carried out between May and September 2023. In 82 out of 151 patients who responded to the invitation, the follow-up time (median (IQR)) was 73.1 (63.6, 81.3) months. A detailed clinical and laboratory evaluation, Schirmer’s test, SGUS using Hočevar scoring system2, and ESSDAI were repeated, and ESSPRI calculated. For the purpose of the study, a cut-off for significant US progression was set at US score change >12 points (from baseline).

Results: Patients’ baseline characteristics are presented in Table 1. At FU visit 43 (52.4%) and 42 (51.2%) patients reported worsening of ocular and oral sicca symptoms. Median ESSPRI at FU was 6.0 (4.0; 6.9) and was at least 5 in 53 (64.6%) patients. There were no significant changes in ESR, gamma globulin level and ESSDAI compared to baseline. None of the included patients developed a new lymphoma during FU. At FU visit 41 (50.0%) patients had US changes consistent with SjD (at baseline 33 (40.2%)). According to the definition, significant increase of US score was found in 18 (21.9%) patients compared to baseline. We found no significant differences in patient age (p=0.516), symptom duration, time (p=0.222), oral dryness (p=1.0), glandular swelling (p=0.722), ESR (p=0.423), gamma globulins (p=0.617), baseline ESSDAI (p=0.352), follow-up ESSPRI (p=0.384) or immunomodulatory treatment (p=1.0) in patients with and without SGUS progression. There was a trend toward higher minor salivary gland focus score in those who US progressed (p=0.091; Fig 1).

Conclusion: Most of the SjD patients in our cohort showed stable glandular disease based on US evaluation. However, one fifth of SjD patients had significant US morphological glandular progression; we found no firm association between patients baseline characteristics or disease activity and US glandular progression.

References:

1. Shiboski CH, et al. Arthritis Rheumatol 2017;69:35–45.

2. Hočevar A et al. Rheumatology 2005;44(6):768-72.

Supporting image 1

Baseline lip biopsy focus score in progressors vs non-progressors.

Supporting image 2

Table 1: SjD patient characteristics at baseline and follow-up visit


Disclosures: K. Perdan Pirkmajer: None; K. Lakota: None; S. Praprotnik: None; Z. Rotar: None; A. Hocevar: None.

To cite this abstract in AMA style:

Perdan Pirkmajer K, Lakota K, Praprotnik S, Rotar Z, Hocevar A. The Value of Ultrasound to Follow Glandular Disease in Sjogren’s Disease Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-value-of-ultrasound-to-follow-glandular-disease-in-sjogrens-disease-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-value-of-ultrasound-to-follow-glandular-disease-in-sjogrens-disease-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology